Botanix Pharmaceuticals taps investors for $40m; Euroz, E&P in tow
Botanix Pharmaceuticals, a listed developer of treatments for skin infections and diseases, was pitching investors for a $40 million equity raise on Monday morning.
The company had Euroz Hartleys and E&P Capital offering shares at 33¢ each – a 7 per cent discount to the last traded price and 13.8 per cent lower than the 10-day volume-weighted average price.
Botanix told investors the funds would accelerate the commercialisation of Sofdra in the United States – a prescription anticholinergic medicine used on the skin to treat excessive underarm sweating.
More to come.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $588.2M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 31.0¢ | 30.0¢ | $2.131M | 7.020M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 504695 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 38124 | 3 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| BOT (ASX) Chart |